Filter your search
Molecular diagnostics include clinical tests with nucleic acid analytes or targets and represent some of the fastest growing and most dynamic clinical diagnostics markets. Exceeding $6 billion in global market volume, clinical molecular diagnostics are the leading application of nucleic acid tests. Kalorama Information offers specialized research in related markets of molecular point-of-care (POC) diagnostics, next-generation sequencing (NGS), molecular infectious disease diagnostics, and cancer diagnostics. Included in this section is information on the latest in molecular screening that catches infectious diseases such as HIV and Influenza, offering developments in the market soon to be used in molecular diagnostic treatments. Find the most up to date information on devices already on the market or still in development that will quickly determine appropriate treatment methods for patients, and understand the paradigm shift from curative medicine to predictive, personalized, and preemptive patient treatment.
- The outbreak of H1N1 (swine flu) highlighted the public health importance of improved testing techniques and providing market opportunities for manufacturers of diagnostic tests and other products related to the disease. These conclusions and others appear in a new report released from Kalorama Information: Swine Flu Market Alert by Kalorama’s lead analyst, Shara Rosen. Regardless […]May 1, 2009$1,500 – $9,990From Kalorama Information a unique tool for assessing the diagnostic business today. Working in conjunction with premier diagnostic survey database Emmes Group, Kalorama Information presents the summarized results from a recent survey of a critical mass of diagnostic labs in the U.S, with analysis from Kalorama’s leading diagnostic analyst, Shara Rosen. Far more than any […]April 1, 2009$3,995 – $7,990Molecular diagnostics represents a revolution postponed, perhaps, but one that is now clearly underway. DNA Testing has emerged fully from research into clinical practice and becoming a dominant platform in clinical medicine. From Emerging to Emergent Technology Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests […]January 1, 2009$2,995 – $5,000A perfect supplemental information resource for customers who have already purchased The Worldwide Market for In Vitro Diagnostic Tests, 6th Edition, The IVD Market Research Supplement bundle studies and quantifies in greater detail some of the important areas that will have a transforming impact on the diagnostic industry: • Companies are now performing diagnostic tests […]August 1, 2008This Kalorama Information report, Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine) is truly a real-world guide to the potential market for companion diagnostics. Essentially the co-development of testing products to enhance the value and efficacy of a therapeutic, companion diagnostics is widely seen as […]June 1, 2008The current population of India is 1.065 billion, and with a growth rate of 1.7%, India will surpass China to become the world’s largest country around 2030. For diagnostic manufacturers, this enormous market is just now being recognized as a high-growth area as the pace of economic growth in India accelerates and modern laboratory practices […]December 1, 2006Interest in and use of the technology has exploded in recent years, thanks to advances in cell biology, biochemical agents, and computer analysis. Research groups around the world are joining the effort to use magnetic, nuclear, and optical imaging techniques to study the molecular interactions that underlie biological processes. This market briefing presents an overview […]June 1, 2005This report covers clinical and drug discovery assay systems that use cells as the basic source material. Sources of the cells to be studied include peripheral blood, cord blood, bone marrow, urine, cerebrospinal and other body fluids and tissue samples. Cell analysis is not a new laboratory procedure. Clinical diagnostics using cells and tissues is […]January 1, 2005$995 – $1,990Gene and chromosome testing for inherited diseases currently represents the third largest molecular diagnostics testing segment in the U.S. Assays in this market address applications in genetic carrier and predisposition testing. Currently, most testing is for prenatal screening and for assessing clinically suspect newborns for various chromosomal abnormalities (e.g., Down’s syndrome, fragile X syndrome). Some […]October 1, 2004$995 – $1,990Currently, the largest market application segment for molecular diagnostics is that for infectious disease testing. The segment is expected to grow at an annual rate between 7% and 8% over the next few years will present some excellent market opportunites for molecular diagnostic competitors. This summary report, extracted from Kalorama Information’s U.S. Market for Molecular […]October 1, 2004
